A Research Study On Cancer Essay

Decent Essays
Cancer remains a leading cause of death in the United States, with 590,000 adults and 2,000 children and adolescents succumbing to this disease in 2015 (NCI, 2016d). The lesser known statistic is that survivorship has more than doubled in 22 years and survivors are expected to comprise more than 5% of the U.S. population by 2024 (NCI, 2016d). Cancer incidence remains relatively unchanged; a contributing cause for increased survivorship is effective therapy (Centers for Disease Control and Prevention, 2004; Simon, 2016). With advances in therapy, multiple therapeutic regimens have been developed for many malignancies. For example, non-small cell lung cancer has over 18 first-line chemotherapeutic regimens listed as a national standard of care (National Comprehensive Cancer Network, 2016). When considering multiple therapeutic regimens, a key deciding factor becomes a patient’s medical fitness for therapy contrasted to a regimen’s toxicity profile. Currently, a gap exists in that toxicity profile: patient reported outcomes. Addressing this gap impacts therapeutic decisions through two pathways: therapeutic dose adjustments (driven by adverse events) as well as empowering patients to understand what to expect during therapy by publicly providing patient-reported outcomes.
Background and Significance
Adverse events are defined by FDA as untoward medical occurrences regardless of causality to a drug. Adverse events define the drug’s toxicity profile, which serves as a
Get Access